Home › Encyclopedia › Tabimorelin: Research Status and Compound Overview
Research / Unapproved

Tabimorelin: Research Status and Compound Overview

Molecular formulaC32H40N4O3
Molecular weight528.7 g/mol
Registered trials0
PubChem CID9810101

What tabimorelin is

Tabimorelin is a synthetic compound identified in chemical databases under PubChem CID 9810101, with a molecular formula of C32H40N4O3 and a molecular weight of about 528.7 g/mol. It has no FDA-approved label, no approved brand name, and no authorized medical use. Any discussion of tabimorelin at this time concerns its chemical identity only, not a demonstrated clinical benefit.

Trial footprint

There are no clinical trials currently registered for tabimorelin in the dataset reviewed. This means there is no publicly tracked record of the compound being studied in human trials as of the data retrieval date. Because no trials are registered, no phase, enrollment, or outcome information is available to summarize.

FAQ

Is tabimorelin FDA approved?
No. Tabimorelin has no FDA-approved label, no approved brand name, and no authorized medical indication. It remains an unapproved research compound.
What is tabimorelin's chemical identity?
Tabimorelin is cataloged in PubChem under CID 9810101, with a molecular formula of C32H40N4O3 and a molecular weight of approximately 528.7 g/mol.
Are there clinical trials studying tabimorelin?
No clinical trials for tabimorelin are currently registered in the dataset reviewed. This means there is no tracked record of ongoing or completed human studies at this time.
What side effects are associated with tabimorelin?
There is no adverse event reporting data available for tabimorelin, so no side effect pattern can be summarized at this time.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem

Updated 2026-11-07